Protein therapeutics: a summary and pharmacological classification

Once a rarely used subset of medical treatments, protein therapeutics have increased dramatically in number and frequency of use since the introduction of the first recombinant protein therapeutic — human insulin — 25 years ago. Protein therapeutics already have a significant role in almost every field of medicine, but this role is still only in its infancy. This article overviews some of the key characteristics of protein therapeutics, summarizes the more than 130 protein therapeutics used currently and suggests a new classification of these proteins according to their pharmacological action.

[1]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[2]  David C James,et al.  Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature? , 2005, Biotechnology and bioengineering.

[3]  E. Erba,et al.  Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone , 2001, British journal of haematology.

[4]  P. Backeljauw,et al.  Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. , 2001, The Journal of clinical endocrinology and metabolism.

[5]  R. Lisker,et al.  Enzyme replacement therapy for primary adult lactase deficiency. Effective reduction of lactose malabsorption and milk intolerance by direct addition of beta-galactosidase to milk at mealtime. , 1984, Gastroenterology.

[6]  P. Wax,et al.  Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. , 2002, Annals of emergency medicine.

[7]  Elizabeth Pennisi,et al.  Gene Counters Struggle to Get the Right Answer , 2003, Science.

[8]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[9]  A. Ganser,et al.  A Randomized , Double-Blind , Placebo-Controlled , Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia , 1997 .

[10]  A. Sherman,et al.  Transgenic chickens as bioreactors for protein-based drugs. , 2005, Drug discovery today.

[11]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[12]  G. Cutler,et al.  Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. , 1999, The Journal of clinical endocrinology and metabolism.

[13]  M. Kaminski,et al.  Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. , 2000, Blood.

[14]  M. Mascelli,et al.  Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development , 2007, Journal of clinical pharmacology.

[15]  E. Frenkel,et al.  Detection and Staging of Small Cell Lung Carcinoma with a Technetium‐labeled Monoclonal Antibody A Comparison with Standard Staging Methods , 1992, Clinical nuclear medicine.

[16]  H A Vrooman,et al.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. , 1999, American journal of respiratory and critical care medicine.

[17]  J. Burke,et al.  A clinical evaluation of enzymatic debridement with papain-urea-chlorophyllin ointment. , 1958, American journal of surgery.

[18]  D. Howrie Growth hormone for the treatment of growth failure in children. , 1987, Clinical pharmacy.

[19]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[20]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[21]  A. Riggs,et al.  Expression in Escherichia coli of chemically synthesized genes for human insulin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Begley,et al.  Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. , 2002, Blood.

[23]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[24]  T. Speroff,et al.  Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. , 2002, Archives of pediatrics & adolescent medicine.

[25]  R. Colvin,et al.  Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. , 1981, Transplantation.

[26]  D. Manninen,et al.  The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin , 1990 .

[27]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[28]  B. Richter,et al.  'Human' insulin versus animal insulin in people with diabetes mellitus. , 2005, The Cochrane database of systematic reviews.

[29]  Sante Tura,et al.  Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.

[30]  T. Simon,et al.  Urokinase in pulmonary embolism. , 1973, Lancet.

[31]  K. Öberg Neuroendocrine gastrointestinal tumours , 1996 .

[32]  Christopher T. Walsh,et al.  Posttranslational Modification of Proteins: Expanding Nature's Inventory , 2005 .

[33]  Christine Katlama,et al.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.

[34]  T. Wieman Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. , 1998, American journal of surgery.

[35]  H. Milgrom,et al.  Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). , 2001, Pediatrics.

[36]  F. Werf A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction , 1998 .

[37]  M. Kaplan,et al.  Treatment of chronic hepatitis C with interferon alfa‐n3: A multicenter, randomized, open‐label trial , 1997, Hepatology.

[38]  M. Oken,et al.  Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.

[39]  Janice M. Reichert,et al.  Development trends for monoclonal antibody cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[40]  L. Moreland,et al.  A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate , 2004, Annals of the rheumatic diseases.

[41]  C. P. Morris,et al.  Human alpha-L-iduronidase: cDNA isolation and expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  W. Gulliver,et al.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. , 2002, Journal of the American Academy of Dermatology.

[43]  T. Casale,et al.  Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. , 2001, JAMA.

[44]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[45]  G. Cheng,et al.  Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. , 2005, Cancer research.

[46]  L. Morales Gaucher's Disease: A Review , 1996, The Annals of pharmacotherapy.

[47]  M. J. Carson,et al.  Clinical studies with glucagon in children. , 1955, The Journal of pediatrics.

[48]  A. Oseroff,et al.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  E. Antman,et al.  Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. , 1990, Circulation.

[50]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[52]  M. Dougados,et al.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.

[53]  Lars Bäckman,et al.  INTERLEUKIN-2-RECEPTOR BLOCKADE WITH DACLIZUMAB TO PREVENT ACUTE REJECTION IN RENAL TRANSPLANTATION , 1998 .

[54]  G. Krueger,et al.  Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. , 2001, The New England journal of medicine.

[55]  L. O. C. Aplan,et al.  SAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE , 2001 .

[56]  E. Arvat,et al.  New approach to the diagnosis of growth hormone deficiency in adults. , 1996, European journal of endocrinology.

[57]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[58]  J L Ritchie,et al.  Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. , 1983, The New England journal of medicine.

[59]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  D. Häussinger,et al.  Gaucher's disease: a review for the internist and hepatologist. , 2000, Hepato-gastroenterology.

[61]  M. Giral,et al.  Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. , 1990, The New England journal of medicine.

[62]  D. F. Moore,et al.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial. , 2001, JAMA.

[63]  J. A. Scarlett,et al.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist , 2001, The Lancet.

[64]  R. Bilous,et al.  HUMAN INSULIN PRODUCED BY RECOMBINANT DNA TECHNOLOGY: SAFETY AND HYPOGLYCÆMIC POTENCY IN HEALTHY MEN , 1980, The Lancet.

[65]  R. Rodriguiz,et al.  Recombinant human interferon gamma therapy for osteopetrosis. , 1992, The Journal of pediatrics.

[66]  Anthony J. Wilkinson,et al.  Protein engineering 20 years on , 2002, Nature Reviews Molecular Cell Biology.

[67]  J. Anderson,et al.  Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. , 1988, Journal of the American College of Cardiology.

[68]  E. Tanzi,et al.  Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. , 1994, The New England journal of medicine.

[69]  E. Haber,et al.  Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. , 1976, The New England journal of medicine.

[70]  A. Menter,et al.  Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. , 2003, JAMA.

[71]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[72]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[73]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[74]  S. Kemp,et al.  Efficacy and safety of mecasermin rinfabate , 2006, Expert opinion on biological therapy.

[75]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .

[76]  R. Taillefer,et al.  Results of the Phase 3 Multicenter Clinical Trial Comparing 99mTc-Apcitide Scintigraphy with Contrast Venography for Imaging Acute DVT , 2000 .

[77]  M. Hayden,et al.  Murine α-l-Iduronidase: cDNA isolation and expression , 1994 .

[78]  Michael Greenberg,et al.  Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.

[79]  J. Vermylen,et al.  A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate , 1993, Thrombosis and Haemostasis.

[80]  I. Mahmood,et al.  Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins , 2005, Clinical pharmacokinetics.

[81]  E. Antman,et al.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.

[82]  Linda Sher,et al.  A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. , 1994, The New England journal of medicine.

[83]  M. Clark,et al.  Antibody humanization: a case of the 'Emperor's new clothes'? , 2000, Immunology today.

[84]  H. Ochs,et al.  Octagam® 5%, an Intravenous IgG Product, Is Efficacious and Well Tolerated in Subjects with Primary Immunodeficiency Diseases , 2004, Journal of Clinical Immunology.

[85]  P. Mannucci,et al.  Treatment of congenital antithrombin III deficiency with concentrates , 1982, British journal of haematology.

[86]  P. Kulkarni,et al.  A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[87]  S. Govender,et al.  Staged reduction and stabilisation in chronic atlantoaxial rotatory fixation. , 2002, The Journal of bone and joint surgery. British volume.

[88]  R. Goode,et al.  VITAMIN E AND OXYGEN CONSUMPTION , 1974 .

[89]  P. Sönksen,et al.  The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. , 1989, The New England journal of medicine.

[90]  T. Voit,et al.  Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial , 2005, Neuromuscular Disorders.

[91]  U. Hedner Dosing with recombinant factor viia based on current evidence. , 2004, Seminars in hematology.

[92]  J. Åman,et al.  Hypoglycaemia in Childhood Diabetes II. , 1988, Acta paediatrica Scandinavica.

[93]  M. Lebwohl,et al.  A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. , 2003, The New England journal of medicine.

[94]  M. Rennels,et al.  Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. , 2003, Pediatrics.

[95]  C. Eng,et al.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. , 2001, The New England journal of medicine.

[96]  C. Ponticelli,et al.  Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[97]  A. Tashjian,et al.  Erratum: Teriparatide human PTH(1-34): 2.5 Years of experience on the use and safety of the drug for the treatment of osteoporosis (Journal of Bone and Mineral Research (March 2006) 21 (354-365)) , 2006 .

[98]  S. Baron,et al.  The interferons. Mechanisms of action and clinical applications. , 1991, JAMA.

[99]  M. Zoller New molecular biology methods for protein engineering. , 1991, Current opinion in biotechnology.

[100]  W. Cefalu,et al.  Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study , 2001, The Lancet.

[101]  E. J. PubMed Citation,et al.  An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction , 2009 .

[102]  J. Reeve Recombinant human parathyroid hormone , 2002, BMJ : British Medical Journal.

[103]  K. Öberg Neuroendocrine gastrointestinal tumours - a condensed overview , 1999 .

[104]  E. Karita,et al.  Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. , 1991, The New England journal of medicine.

[105]  C. Dobson,et al.  Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[106]  B. Tarlatzis,et al.  The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. , 2006, Human reproduction.

[107]  J. Belmont,et al.  Enzyme-replacement therapy in mucopolysaccharidosis I. , 2001, The New England journal of medicine.

[108]  Assent investigators Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.

[109]  W. V. Mieghem A comparison of continuous infusion of alteplase with double bolus administration for acute myocardial infarction: the continuous infusion versus double double bolus administration of alteplase , 1997 .

[110]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[111]  E. Ghigo,et al.  The diagnosis of growth hormone deficiency (GHD) in adults. , 1995, The Journal of clinical endocrinology and metabolism.

[112]  M. Levy,et al.  Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. , 2002, JAMA.

[113]  A. Nissenson,et al.  National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[114]  C. Eng,et al.  A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) , 2006, Genetics in Medicine.

[115]  D. Goldenberg,et al.  Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma , 2000, Cancer.

[116]  L. Holle Pegaspargase: An Alternative? , 1997, The Annals of pharmacotherapy.

[117]  B H Perry,et al.  Efficacy and safety of becaplermin (recombinant human platelet‐derived growth factor‐BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[118]  Orton,et al.  INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .

[119]  P. Jungers,et al.  RANDOMISED PLACEBO-CONTROLLED TRIAL OF HEPATITIS B SURFACE ANTIGEN VACCINE IN FRENCH HAEMODIALYSIS UNITS: I, MEDICAL STAFF , 1981, The Lancet.

[120]  J. Hoefs,et al.  Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial , 1997 .

[121]  G. B. Dowling,et al.  Vitamin D in cutaneous tuberculosis. , 1947, Lancet.

[122]  Lawrence Blonde,et al.  Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.

[123]  R. Testa,et al.  Long‐term follow up of chronic hepatitis C patients after α‐interferon treatment: A functional study , 2001, Journal of gastroenterology and hepatology.

[124]  P. Meusers,et al.  Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. , 1991, The New England journal of medicine.

[125]  N. Olsen,et al.  New drugs for rheumatoid arthritis. , 2004, The New England journal of medicine.

[126]  Thomas C. Südhof,et al.  Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 , 1993, Nature.

[127]  G. Albers,et al.  Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. , 2000, JAMA.

[128]  Carl-Gustaf Rosen,et al.  Process Economics of Animal Cell and Bacterial Fermentations: A Case Study Analysis of Tissue Plasminogen Activator , 1993, Bio/Technology.

[129]  J. B. Collip,et al.  Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. 1922. , 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[130]  F. Mandelli,et al.  Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. , 1990, The New England journal of medicine.

[131]  A. Laupacis Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group. , 1990, Seminars in nephrology.

[132]  H. C. Coelingh Bennink,et al.  Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. , 1997, Fertility and sterility.

[133]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[134]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[135]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[136]  G. Zych,et al.  Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in the Treatment of Tibial Nonunions: A Prospective, Randomized Clinical Trial Comparing rhOP-1 with Fresh Bone Autograft* , 2001, The Journal of bone and joint surgery. American volume.

[137]  B. Coiffier,et al.  Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1993, The New England journal of medicine.

[138]  oseph,et al.  PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .

[139]  D. Manninen,et al.  The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. , 1990, JAMA.

[140]  David Hunt,et al.  ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .

[141]  L. Becker,et al.  Antimyosin imaging in acute transmural myocardial infarctions: results of a multicenter clinical trial. , 1989, Journal of the American College of Cardiology.

[142]  H. Fuchs,et al.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.

[143]  M. Ho,et al.  Gaucher's disease: deficiency of 'acid' -glucosidase and reconstitution of enzyme activity in vitro. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[144]  M. Haase Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2002, Blood.

[145]  S. Orkin,et al.  Partial Correction of the Phagocyte Defect in Patients with X-Linked Chronic Granulomatous Disease by Subcutaneous Interferon Gamma , 1988 .

[146]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  R. Schiffmann,et al.  Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources , 1995, Annals of Internal Medicine.

[148]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.

[149]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[150]  R. Coler,et al.  Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test. , 2001, Tuberculosis.

[151]  G. Rosen,et al.  A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. , 1996, Blood.

[152]  T. Shea,et al.  Palifermin for oral mucositis after intensive therapy for hematologic cancers , 2017 .

[153]  P. Watkins,et al.  BIOSYNTHETIC HUMAN INSULIN IN THE TREATMENT OF DIABETES A Double-blind Crossover Trial in Established Diabetic Patients , 1982, The Lancet.

[154]  R. Rosenberg Actions and interactions of antithrombin and heparin. , 1975, The New England journal of medicine.

[155]  T. Investigators,et al.  A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .

[156]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  J. Soulillou,et al.  Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients , 1997, The Lancet.

[158]  A. Phelan,et al.  Intercellular delivery of functional p53 by the herpesvirus protein VP22 , 1998, Nature Biotechnology.

[159]  M. Gordon The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria , 2008 .

[160]  J. Sninsky,et al.  Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. , 1991, The New England journal of medicine.

[161]  J. Manning,et al.  Treatment of hairy cell leukemia with recombinant α-interferon , 1986 .

[162]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[163]  A. Friedman-kien Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived). , 1995, American journal of obstetrics and gynecology.

[164]  J. Burgess,et al.  Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments , 1990 .

[165]  E. Braunwald,et al.  RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM , 1988, The Lancet.

[166]  K. Goa,et al.  Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. , 2003, Drugs.

[167]  A. Boxer,et al.  Debridement of dermal ulcers and decubiti with collagenase. , 1969, Geriatrics.

[168]  J. Ritz,et al.  Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[169]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[170]  J. Mullane,et al.  Effects of Pramlintide, an Analog of Human Amylin, on Plasma Glucose Profiles in Patients With IDDM: Results of a Multicenter Trial , 1997, Diabetes.

[171]  D. Goodin,et al.  Randomized, comparative study of interferon &bgr;-1a treatment regimens in MS: The EVIDENCE Trial , 2002 .

[172]  E. Thorland,et al.  Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[173]  R. D. de Man,et al.  Long‐term follow‐up of alpha‐interferon treatment of patients with chronic hepatitis B , 2004, Hepatology.

[174]  E. Gordon,et al.  A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. , 1994, Blood.

[175]  M. E. Reid,et al.  Thrombocytopenia caused by the development of antibodies to thrombopoietin , 2002 .

[176]  T. Wieman Clinical efficacy of becaplermin (rhPDGF-BB) gel , 1998 .

[177]  L. Wilkins Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial , 2003, Neurology.

[178]  S. Malawista,et al.  A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. , 1998, The New England journal of medicine.

[179]  T. Quattrin,et al.  Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.

[180]  P. Banks,et al.  Does pancreatic enzyme supplementation reduce pain in patients with chronic pancreatitis: a meta-analysis. , 1997, The American journal of gastroenterology.

[181]  E. Keeffe,et al.  Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. , 1997, Hepatology.

[182]  A D Shapiro,et al.  Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.

[183]  A. Burgess,et al.  Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor , 1992 .

[184]  S. Boden,et al.  The Use of rhBMP-2 in Interbody Fusion Cages: Definitive Evidence of Osteoinduction in Humans: A Preliminary Report , 2000, Spine.

[185]  K. Doody,et al.  Use of recombinant human chorionic gonadotropin in ovulation induction. , 2003, Fertility and sterility.

[186]  Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. , 1995, Neurology.

[187]  S. Sarker,et al.  Effect of hyaluronidase on ocular motility and eyelid function in sub-Tenon's anaesthesia: randomised controlled trial , 2006, Eye.

[188]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[189]  M. Atkins,et al.  High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.

[190]  F. Wurm,et al.  Large-scale transient expression in mammalian cells for recombinant protein production. , 1999, Current opinion in biotechnology.

[191]  J. Arnout,et al.  Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. , 1993, Blood.

[192]  K. Lindsay Therapy of hepatitis C: Overview , 1997, Hepatology.

[193]  N. Sifontis IMMUNOSUPPRESSIVE STRATEGIES IN SOLID ORGAN TRANSPLANTATION , 2006 .

[194]  E. Estey,et al.  Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia , 2003, Cancer.

[195]  Janice M. Reichert,et al.  A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States , 2003, Nature Reviews Drug Discovery.

[196]  L. Hellgren Cleansing properties of stabilized trypsin and streptokinase-streptodornase in necrotic leg ulcers , 2004, European Journal of Clinical Pharmacology.

[197]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[198]  R. Coler,et al.  Cloning of a Mycobacterium tuberculosis gene encoding a purifed protein derivative protein that elicits strong tuberculosis-specific delayed-type hypersensitivity. , 2000, The Journal of infectious diseases.

[199]  Lieschke Gj,et al.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). , 1992, The New England journal of medicine.

[200]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[201]  C. Abildgaard,et al.  Treatment of hemophilia with glycine-precipitated factor 8. , 1966, The New England journal of medicine.

[202]  E. Ghigo,et al.  The diagnosis of growth hormone deficiency in adults. , 1997, The Journal of clinical endocrinology and metabolism.

[203]  D D Peterson,et al.  A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[204]  E. Braunwald,et al.  Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion , 1993, The Lancet.

[205]  B. Chaitman,et al.  Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. , 1995, The New England journal of medicine.

[206]  E. Schiff,et al.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1990, The New England journal of medicine.

[207]  J. Hecht,et al.  A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. , 2006, Clinical colorectal cancer.

[208]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[209]  P. Wille-Jørgensen,et al.  A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. , 1997, The New England journal of medicine.

[210]  R. Taillefer,et al.  Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter Trial Investigators. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[211]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[212]  Paty Dw,et al.  Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. , 2001, Neurology.

[213]  J. Egrie,et al.  Development and characterization of novel erythropoiesis stimulating protein (NESP) , 2001, British Journal of Cancer.

[214]  S. Garger,et al.  Making an ally from an enemy: plant virology and the new agriculture. , 2002, Annual review of phytopathology.

[215]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[216]  B. Thiers Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition , 2006 .

[217]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[218]  R. Fleischmann,et al.  Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. , 2004, Journal of Rheumatology.

[219]  T. Stijnen,et al.  Growth hormone treatment in growth-retarded adolescents after renal transplant , 1994, The Lancet.

[220]  A. Ghezzi,et al.  Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) , 2002, The Lancet.

[221]  S. Lamberts,et al.  Drug therapy : octreotide , 1996 .

[222]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[223]  M. Kosinski,et al.  GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side , 2007, Clinical pharmacology and therapeutics.

[224]  C. Kessler,et al.  Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2001, Blood.

[225]  A. Buist,et al.  Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. American Thoracic Society. , 1989, The American review of respiratory disease.

[226]  J. Jankovic,et al.  Therapeutic uses of botulinum toxin. , 1991, The New England journal of medicine.

[227]  Scott D. Putney,et al.  Improving protein therapeutics with sustained-release formulations , 1998, Nature Biotechnology.

[228]  E. Karita,et al.  Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. , 1991, Disease markers.

[229]  E. Colman,et al.  A brief history of calcitonin , 2002, The Lancet.

[230]  F. Werf Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[231]  R. Wilcox,et al.  Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence International Joint Efficacy Comparison of Thrombolytics , 1995, The Lancet.

[232]  J. Katz,et al.  Factor IX inhibitors and anaphylaxis in hemophilia B. , 1997, Haemophilia : the official journal of the World Federation of Hemophilia.

[233]  C. Schmid,et al.  Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. , 1998, The New England journal of medicine.

[234]  L. Rogers,et al.  Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature. , 1990, The American journal of medicine.

[235]  G. Raghu,et al.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.

[236]  D. Goodin,et al.  Randomized, comparative study of interferon β-1a treatment regimens in MS , 2002, Neurology.

[237]  R. Rodriguiz,et al.  Long-term treatment of osteopetrosis with recombinant human interferon gamma. , 1995, The New England journal of medicine.

[238]  M. Dreyer,et al.  Efficacy and safety of insulin glulisine in patients with type 1 diabetes. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[239]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[240]  U. Janssens,et al.  Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. , 1999, Circulation.

[241]  N. Petrelli,et al.  Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. , 1997, Annals of surgery.

[242]  Daniel E. Otzen,et al.  Protein drug stability: a formulation challenge , 2005, Nature Reviews Drug Discovery.

[243]  R. Wilcox Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence: International Joint Efficacy Comparison of Thrombolytics , 1995 .

[244]  L. Gullo,et al.  Treatment of type II gastric carcinoid tumors with somatostatin analogues. , 2000, The New England journal of medicine.

[245]  P. R. Frederick,et al.  A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. , 1983, The New England journal of medicine.

[246]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[247]  A. Furlan,et al.  Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. , 2000, JAMA.

[248]  A. Tashjian,et al.  Teriparatide [Human PTH(1‐34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[249]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[250]  T. Tango,et al.  A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

[251]  P. Fishman,et al.  CuZn Superoxide Dismutase (SOD-1):Tetanus Toxin Fragment C Hybrid Protein for Targeted Delivery of SOD-1 to Neuronal Cells (*) , 1995, The Journal of Biological Chemistry.

[252]  John C. Davis,et al.  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. , 2002, The New England journal of medicine.

[253]  T. Mor,et al.  Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. , 2002, Trends in molecular medicine.

[254]  R. Gelber,et al.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.

[255]  J. Garber,et al.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.

[256]  C. Lunan,et al.  Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. , 2004, European journal of obstetrics, gynecology, and reproductive biology.

[257]  J. A. Scarlett,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000, The New England journal of medicine.

[258]  P. Mease,et al.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial , 2000, The Lancet.

[259]  M. Houghton,et al.  Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay , 1991, The Lancet.

[260]  M. L. Gross Ethics, Policy, and Rare Genetic Disorders: The Case of Gaucher Disease in Israel , 2002, Theoretical medicine and bioethics.

[261]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[262]  E. Topol,et al.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.

[263]  E. Georgiev,et al.  Collagenase in the Treatment of Dermal and Decubitus Ulcers , 1975, Journal of the American Geriatrics Society.

[264]  L. Braverman,et al.  Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). , 1994, The Journal of clinical endocrinology and metabolism.

[265]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[266]  A. Crandall,et al.  A comparison of topical and retrobulbar anesthesia for cataract surgery. , 1996, Ophthalmology.

[267]  F. Benfenati,et al.  Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin , 1992, Nature.

[268]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[269]  D. Schoenfeld,et al.  Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. , 1992, The Journal of clinical endocrinology and metabolism.

[270]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[271]  R. Kobayashi,et al.  Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.

[272]  T. Benyo,et al.  Letter: Inhibition of labour by prostaglandin antagonists in impending abortion and preterm and term labour. , 1974, Lancet.

[273]  K. Goa,et al.  Alglucerase. A review of its therapeutic use in Gaucher's disease. , 1992, Drugs.

[274]  R. Heine,et al.  Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes , 2005, Annals of Internal Medicine.

[275]  J. Dhainaut,et al.  Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsis , 2004, Critical care medicine.

[276]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[277]  S. Richards,et al.  UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.

[278]  K. Mergener,et al.  A double‐blind, randomized, dose response study testing the pharmacological efficacy of synthetic porcine secretin , 2000, Alimentary pharmacology & therapeutics.

[279]  L. Somogyi,et al.  Comparison of Biologic Porcine Secretin, Synthetic Porcine Secretin, and Synthetic Human Secretin in Pancreatic Function Testing , 2003, Pancreas.

[280]  John M. Woodley,et al.  Fluid mixing in shaken bioreactors: Implications for scale-up predictions from microlitre-scale microbial and mammalian cell cultures , 2006 .

[281]  S. Santavirta,et al.  Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures: A Prospective, Controlled, Randomized Study of Four Hundred and Fifty Patients , 2002, The Journal of bone and joint surgery. American volume.

[282]  R. Maguire,et al.  Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site‐specific immunoconjugates , 1993 .

[283]  P. Toskes,et al.  Protease-specific suppression of pancreatic exocrine secretion , 1984 .

[284]  Jozef Arnout,et al.  Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. , 1993 .

[285]  G. Sibbald,et al.  Recombinant human platelet‐derived growth factor‐BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open‐label clinical evaluation of efficacy , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[286]  James B. Young Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[287]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[288]  S. Baron,et al.  The interferons. Mechanisms of action and clinical applications. , 1991, JAMA.

[289]  W. Chapman,et al.  A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. , 2007, Journal of the American College of Surgeons.

[290]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[291]  M. Thakur,et al.  Neutrophil-specific 99mTc-labeled anti-CD15 monoclonal antibody imaging for diagnosis of equivocal appendicitis. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[292]  R. Dart,et al.  Efficacy, safety, and use of snake antivenoms in the United States. , 2001, Annals of emergency medicine.

[293]  M. Kaplan,et al.  A RANDOMIZED CLINICAL TRIAL COMPARING OKT3 AND STEROIDS FOR TREATMENT OF HEPATIC ALLOGRAFT REJECTION , 1987, Transplantation.

[294]  G. Burmester,et al.  Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. , 2003, Arthritis and rheumatism.

[295]  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. , 1998, Lancet.

[296]  H. Urnovitz,et al.  Increased sensitivity of HIV-1 antibody detection , 1997, Nature Medicine.

[297]  J. Stockman AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP , 2008 .

[298]  J. Duchin,et al.  Comparison of sensitivities to two commercially available tuberculin skin test reagents in persons with recent tuberculosis. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[299]  R. Fisher,et al.  A phase 2 trial of CHOP chemotherapy followed by tositumomab / iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S 9911 , 2003 .

[300]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[301]  M. Ranke,et al.  Testing with growth hormone-releasing factor (GRF(1–29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency , 1986, European Journal of Pediatrics.

[302]  G. Bakale,et al.  Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. , 2000, Urology.

[303]  S. Tyring,et al.  Interferons in human papillomavirus infections. , 1994, Antiviral research.

[304]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[305]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[306]  R. Fisher,et al.  A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. , 2003, Blood.

[307]  M. Cairo,et al.  A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. , 2001, Blood.

[308]  B. Weissmann,et al.  The defect in the Hurler and Scheie syndromes: deficiency of -L-iduronidase. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[309]  Gerald R. Williams,et al.  Complications of Thermal Capsulorrhaphy of the Shoulder , 2001, The Journal of bone and joint surgery. American volume.

[310]  R. Levy,et al.  Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[311]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.